Treatment strategies for Zollinger-Ellison syndrome

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1145-1157

  Wilcox, C Mel ^a   Hirschowitz, Basil I ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Gastric acid hypersecretion; Neuroendocrine tumor; Proton pump inhibitors; Zollinger Ellison syndrome

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DEXLANSOPRAZOLE; ESOMEPRAZOLE; FAMOTIDINE; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SOMATOSTATIN RECEPTOR; TAK 390; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CYANOCOBALAMIN DEFICIENCY; DIAGNOSTIC IMAGING; DIARRHEA; DRUG DOSE TITRATION; ENDOSCOPIC ECHOGRAPHY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; HEARTBURN; HIP FRACTURE; HUMAN; HYPOMAGNESEMIA; IMAGE ANALYSIS; MORBIDITY; MORTALITY; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA; PEPTIC ULCER; REVIEW; SCINTIGRAPHY; STOMACH ACID; STOMACH SECRETION; SYMPTOM; VOMITING; WEIGHT REDUCTION; ZOLLINGER ELLISON SYNDROME; PATHOPHYSIOLOGY; PROGNOSIS;

HISTAMINE H2 ANTAGONISTS; HUMANS; PROGNOSIS; PROTON PUMP INHIBITORS; ZOLLINGER-ELLISON SYNDROME;

EID: 67649512887     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902887035     Document Type: Review

References (134)

1. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-723 • The initial description of this syndrome.
2. Kirsner JB, Levin E, Palmer WL. Observations on the excessive nocturnal gastric secretion in patients with duodenal ulcer. Gastroenterology 1948;11:598-617
3. Gregory RA, Tracy HJ, French JM, Sircus W. Extraction of gastrin-like substance from a pancreatic tumour in a case of Zollinger-Ellison syndrome. Lancet 1960;1:1045-1048
4. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006;84:173-182 (Pubitemid 46361051)
5. Fendrich V, Langer P, Waldmann J, et al. Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 2007;94:1331-1341 (Pubitemid 350144380)
6. Way L, Goldman L, Dunphy JE. Zollinger-Ellison syndrome. An analysis of twenty-five cases. Am J Surg 1968;116:293-304
7. Soga J, Yakuwa Y. The gastrinoma/ Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hep Bil Pancr Surg 1998;5:77-85 (Pubitemid 128662561)
8. Nikou GC, Toubanakis C, Nikolaou P, et al. Gastrinomas associated with MEN 1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005;52:1668-1676 (Pubitemid 41745608)
9. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome; re-appraisal and evaluation of 260 registered cases. Ann Surg 1964;160:512-528
10. Ruszniewski P, Podevin P, Cadiot G, et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type 1 multiple endocrine neoplasia. Pancreas 1993;8:295-304 (Pubitemid 23119100)
11. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671 (Pubitemid 33152604)
12. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine 2004;83:43-83 (Pubitemid 38124855)
13. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004;240:757-773 • A thoughtful review of the current issues regarding surgical management of Zollinger-Ellison syndrome. (Pubitemid 39425767)
14. Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg 2006;30:1-11 (Pubitemid 43081606)
15. Kaplan EL, Horvath K, Udekwu A, et al. Gastrinomas: a 42-year-experience. World J Surg 1990;14:365-375
16. Thompson JC, Reeder DD, Villar HV, Fender R. Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome. Surg Gynecol Obstet 1975;140:721-739
17. Quatrini M, Castoldi L, Rossi G, et al. A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002. Effects of surgical and medical treatments on long-term survival. J Clin Gastroenterol 2005;39:376-380
18. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 2000;79:379-411 • Largest series reporting the manifestations of Zollinger-Ellison syndrome. Comparisons to the world's literature at that time were also made.
19. Zollinger RM, Grant GN. Ulcerogenic tumor of the pancreas. JAMA 1964;190:181-184
20. Hoffmann KM, Gibril F, Entsuah LK, et al. Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J Clin Endocrinol Metab 2006;91:204-212 (Pubitemid 43069139)
21. Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromomaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008;93:1582-1591 (Pubitemid 351656492)
22. Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002;123:68-85 (Pubitemid 34747527)
23. Grama D, Eriksson B, Mårtensson H, et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992;16:632-639
24. Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001;15:1555-1561
25. Ellison EC, Sparks J. Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors? Am J Surg 2003;186:245-248
26. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome. 1. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and Comparison with 2229 cases from the literature. Medicine 2006;85:295-330
27. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine 2001;80:189-222 • Extensive evaluation reporting gastric acid secretion. The results of this prospective study were compared with the world's literature.
28. Berna ML, Hoffmann M, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome. II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine 2006;85:331-364
29. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med 1994;97:436-444 (Pubitemid 24345595)
30. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341:635-644 • Often-quoted study suggesting that cure is possible with surgery in Zollinger-Ellison syndrome.
31. Thom AK, Norton JA, Axiotis CA, Jensen RT. Location, incidence, and malignant potential of duodenal gastrinomas. Surgery 1991;110:1086-1091
32. Pfannenberg AC, Burkart C, Kröber SM, et al. Dual-phase multidetector thin-section CT in detecting duodenal gastrinoma. Abdom Imaging 2005;30:543-547 (Pubitemid 41446671)
33. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125:26-34 (Pubitemid 126505336)
34. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335-347 (Pubitemid 27078820)
35. Cadiot G, Bonnaud G, Lebtahi R, et al. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gut 1997;41:107-114 (Pubitemid 27351649)
36. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998;228:228-238 (Pubitemid 30191719)
37. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN 1). Surg Oncol 2003;12:145-151
38. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 1998;16:1040-1053 (Pubitemid 28108739)
39. Mclean AM, Fairclough PD. Endoscopic ultrasound in the localization of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab 2005;19:177-193 (Pubitemid 40347810)
40. Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271-2277 (Pubitemid 30707388)
41. Ruszniewski P, Amouyal P, Amouyal G, et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995;117:629-635
42. Chatzipantelis P, Salla C, Konstantinou P, et al. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors. A study of 48 cases. Cancer (Cancer Cytopathol) 2008;114:255-262
43. Hirschowitz BI, Worthington J, Mohnen J, Haber M. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther 2007;26:869-878 (Pubitemid 47346715)
44. Nikou GC, Marinou K, Thomakos P, et al. Chromagranin A levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 2008;8:510-519
45. Abou-Saif A, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 2003;98:249-261 (Pubitemid 36828447)
46. Bashir S, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther 2002;16:1367-1382 (Pubitemid 34888370)
47. Donow C, Pipeleers-Marichal M, Schröder S, et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 1991;68:29-34
48. Klöppel G, Anlauf M. Gastrinoma - morphological aspects. Wien Klin Wochenschr 2007;20:579-584 (Pubitemid 350060666)
49. Thompson NW, Vinik AI, Eckhauser FE. Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg 1989;209;396-404
50. Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004;239:617-626
51. Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990;322:723-727 (Pubitemid 20092807)
52. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-Type 1 and Zollinger-Ellison Syndrome. Ann Surg 2008;247:501-510
53. Shepherd JJ, Challis DR, Davies PF, et al. Multiple endocrine neoplasm, type 1. Gastrinomas, pancreatic neoplasms, microcarcinoids, the Zollinger-Ellison syndrome, lymph nodes, and hepatic metastases. Arch Surg 1993;128:1133-1142
54. Pipeleers-Marichal M, Donow C, Heitz PU, Klöppel G. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type 1. World J Surg 1993;17:481-488 (Pubitemid 23228401)
55. Le Bodic MF, Heymann MF, Lecomte M, et al. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type 1. Am J Surg Path 1996;20:1378-1384 (Pubitemid 26367209)
56. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006;30:560-574 • A case report documenting that minute foci of gastrinoma in the small bowel may be associated with duodenal nodal involvement. (Pubitemid 44265008)
57. Kann PH, Balakina E, Ivan D, et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 2006;13:1195-1202 (Pubitemid 46212573)
58. Zogakis TG, Gibril F, Libutti SK, et al. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg 2003;238:42-48 (Pubitemid 38176406)
59. Anlauf M, Enosawa T, Henopp T, et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN 1 patient. The need for a systematic search for the primary tumor. Am J Surg Pathol 2008;32:1101-1105
60. Müssig K, Wehrmann M, Horger M, et al. Lymph node gastrinoma in multiple endocrine neoplasia type 1 - a diagnostic challenge. Exp Clin Endocrinol Diabetes 2008;116:554-557
61. Norton JA, Alexander HR, Fraker DL, et al. Possible primary lymph node gastrinoma: occurrence, natural history and predictive factors. Ann Surg 2003;237:650-659 (Pubitemid 38174531)
62. Deveney CW, Deveney KS, Way LW. The Zollinger-Ellison syndrome - 23 years later. Ann Surg 1978;188:384-391 (Pubitemid 9018183)
63. Thompson JC, Lewis BG, Wiener I, Townsend CM. The role of surgery in the Zollinger-Ellison syndrome. Ann Surg 1983;197:594-604
64. Malagelada JR, Edis AJ, Adson MA, et al. Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 1983;84:1524-1532
65. Norton JA, Jensen RT. Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg 2007;205:S34-7 (Pubitemid 47488912)
66. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006;244:410-419 • This study compares survival rates in those with surgery compared with those who did not undergo surgical resection. The results indicate surgery increases survival. (Pubitemid 44273579)
67. Åerström G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck's Arch Surg 2002;386:558-569 (Pubitemid 34285635)
68. Friesen SR. Treatment of the Zollinger-Ellison syndrome. A 25-year assessment. Am J Surg 1982;143:331-338
69. Alexander HR, Bartlett DL, Venson DJ, et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery 1998;124:1160-1166 (Pubitemid 28555209)
70. Richardson CT, Feldman M, Mcclelland RN, et al. Effect of vagotomy in Zollinger-Ellison syndrome. Gastroenterology 1979;77:682-686 (Pubitemid 9249368)
71. Richardson CT, Peters MN, Feldman M, et al. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists. A prospective study. Gastroenterology 1985;89:357-367 (Pubitemid 15028593)
72. Macfarlane MP, Fraker DL, Alexander R, et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 1995;118:973-980
73. Bartsch DK, Langer P, Wild A, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery 2000;128:958-966 • A surgical series suggesting that, with aggressive resection including Whipple procedure, long-term cure may be possible.
74. Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006;244:61-70 (Pubitemid 44297449)
75. Grama D, Skogseid B, Wilander E, et al. Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992;16:611-618
76. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001;234:495-506 (Pubitemid 32946712)
77. Hausman MS, Thompson NW, Gauger PG, Doherty GM. The surgical management of MEN 1 pancreatoduodenal neuroendocrine disease. Surgery 2004;136:1205-1211 (Pubitemid 39647535)
78. Brogden RN, Heel RC, Speight TM, Avery GS. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs 1978;15:93-131 (Pubitemid 8266264)
79. Mignon M. Diagnostic and therapeutic strategies in Zollinger-Ellison syndrome associated with multiple endocrine neoplasia type 1 (MEN 1): experience of the Zollinger-Ellison Syndrome Research Group: Bichat 1958-1999). Bull Acad Natl Med 2003;187:1249-1258
80. Pisegna JR, Norton JA, Slimak GG, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992;102:767-778
81. Pisegna JR, Norton JA, Slimak GG, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992;102:767-778
82. Metz DC, Benya RV, Fishbeyn VA, et al. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther 1993;7:247-257 (Pubitemid 23198299)
83. Mccarthy DM. Report on the United States experience with cimetidine in Zollinger-Ellison syndrome and other hypersecretory states. Gastroenterology 1978;74:453-458 (Pubitemid 8276597)
84. Mccarthy DM, Olinger EJ, May RJ, et al. H2-histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy. Ann Intern Med 1977;87:668-675
85. Bonfils S, Mignon M, Gratton J. Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome. World J Surg 1979;20:597-604 (Pubitemid 10248179)
86. Deveney CW, Stein S, Way LW. Cimetidine in the treatment of Zollinger-Ellison syndrome. Am J Surg 1983;146;116-123
87. Crane SA, Summers RW, Heeringa WG. Long-term cimetidine and anticholinergic therapy in patients with gastrinoma. Am J Surg 1979;138:46-50 (Pubitemid 10236958)
88. Mignon M, Vallot T, Galmiche JP, et al. Interest of a combined antisecretory treatment, cimetidine and pirenzepin, in the management of severe forms of Zollinger-Ellison syndrome. Digestion 1980;20:56-61 (Pubitemid 10032517)
89. Ziemniak JA, Madura M, Adamonis AJ, et al. Failure of cimetidine in Zollinger-Ellison syndrome. Dig Dis Sci 1983;28:976-980 (Pubitemid 14232081)
90. Groarke JF, Haggstrom GD, Halpern NB, Hirschowitz BI. Zollinger-Ellison syndrome unresponsive to cimetidine. Am J Gastroenterol 1979;72:168-170 (Pubitemid 9235971)
91. Mignon M, Vallot TH, Mayeur S, Bonfils S. Ranitidine and cimetidine in Zollinger-Ellison syndrome. Br J Clin Pharmac 1980;10:173-174
92. Habal FM, Soldin SJ, Greenberg GR. Cimetidine-resistant Zollinger-Ellison syndrome: successful management with ranitidine. Can Med Assoc J 1983;129:256-258
93. Collen MJ, Howard JM, McArthur KE, et al. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 1984;100:52-58 (Pubitemid 14219129)
94. Jensen RT, Collen MJ, McArthur KE, et al. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. Am J Med 1984;77:90-105 (Pubitemid 15175991)
95. Jensen RT, Collen MJ, Pandol SJ, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 1983;308:883-887
96. Berardi RR, Tankanow RM, Nostrant TT. Comparison of famotidine with cimetidine and ranitidine. Clin Pharm 1988;7:271-284 (Pubitemid 18119103)
97. Campoli-Richards DM, Clissold SP. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:197-221 (Pubitemid 16050171)
98. Howard JM, Vinayek R, Maton PN, et al. Famotidine: effective treatment of Zollinger-Ellison syndrome. J Clin Gastroenterol 1987;9(Suppl. 2):23-25 (Pubitemid 17118615)
99. Howard JM, Chremos AN, Collen MJ, et al. Ramotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985;88:1026-1033 (Pubitemid 15105898)
100. Maton PN. Role of acid suppressants in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1991;5(Suppl. 1):25-35
101. Vinayek R, Amantea MA, Maton PN, et al. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology 1991;101:138-147
102. Metz DC, Forsmark C, Lew EA, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 2001;96:3274-3280 (Pubitemid 34016648)
103. Ramdani A, Mignon M, Samoyeau R. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterol Clin Biol 2002;26:355-359 (Pubitemid 34555809)
104. Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006;23:437-444 (Pubitemid 43382024)
105. Morocutti A, Merrouche M, Bjaaland T, et al. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther 2006;24:1439-1444 (Pubitemid 44657120)
106. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005;3:39-48 • Longest follow-up studies using a proton pump inhibitor for the treatment of Zollinger-Ellison syndrome. (Pubitemid 40092942)
107. Pospaï D, Cadiot G, Forestier S, et al. Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment. Gastroenterol Clin Biol 1998;80:1-8
108. Mayer A, Sheiner E, Holcberg G. Zollinger-Ellison syndrome, treated with lansoprazole, during pregnancy. Arch Gynecol Obstet 2007;276:171-173 (Pubitemid 47022945)
109. Mckeage K, Blick SK, Croxtall JD, et al. Esomeprazole: a review of its use in the management of gastric acid-related disease in adults. Drugs 2008;68:1571-1607 (Pubitemid 352001193)
110. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102:2648-2654 (Pubitemid 350179329)
111. Metz DC, Howden CW, Perez MC, et al. Tak-390MR, a proton pump inhibitor with a novel dual delayed release formulation, maintains healing and controls heartburn in GERD patients with healed erosive esophagitis. Gastroenterology 2008;134(4 Suppl 1):A-171
112. Zhang W, Wu J, Vakily M. Pharmacokinetics of TAK-390MR (modified release) 30, 60, and 90 mg in subjects with symptomatic, non-erosive gastroesophageal reflux disease (GERD). Clin Pharmacol Ther 2008;83(Suppl 1):S96
113. Mayer MD, Vakily M, Witt G, Mulford DJ. The pharmacokinetics of TAK-390mr 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis. Gastroenterology 2008;134(Suppl 1):A-176
114. Fraker DL, Norton JA, Saeed ZA, et al. A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery 1988;104:1054-1063 (Pubitemid 19011986)
115. Saeed ZA, Norton JA, Frank WO, et al. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 1989;96:1393-1402 (Pubitemid 19138678)
116. Maton PN. Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion. Drugs 1996;52:33-44
117. Stewart CA, Termiani B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998;12:83-98 (Pubitemid 28057410)
118. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-1121 (Pubitemid 351614880)
119. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-430 (Pubitemid 28274845)
120. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953 (Pubitemid 46021498)
121. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326
122. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-959
123. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391-398
124. Dalton BR, Lye-Maccannell T, Henderson EA, et al. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009;29:626-634
125. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999;17:615-630 (Pubitemid 29075250)
126. Weber HC, Venzon DJ, Lin J-T, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995;108:1637-1649 • A large prospective study that reports factors associated with long-term survival in Zollinger-Ellison syndrome.
127. Stabile BE, Passaro E. Benign and malignant gastrinoma. Am J Surg 1985;149:144-150 (Pubitemid 15156170)
128. Mignon M, Ruszniewski P, Podevin P, et al. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type 1. World J Surg 1993;17:489-497 (Pubitemid 23228402)
129. Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006;243:265-272 (Pubitemid 43185447)
130. Cadiot G, Vuagnat A, Doukhan I, et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999;116:286-293 (Pubitemid 29055350)
131. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997;15:2420-2431 (Pubitemid 27251146)
132. Konturek SJ, Konturek PC, Bielañski W, et al. Case presentation of gastrinoma combined with gastric carcinoid with the longest survival record - Zollinger-Ellison syndrome: pathophysiology, diagnosis and therapy. Med Sci Monit 2002;8:CS43-59 (Pubitemid 34694660)
133. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992;103:1498-1508
134. Termanini B, Gibril F, Stewart CA, et al. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996;10:61-71 (Pubitemid 26070002)